Quanterix (NASDAQ:QTRX) Issues Earnings Results

Quanterix (NASDAQ:QTRX) posted its quarterly earnings results on Monday. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.63), FiscalAI reports. The company had revenue of $32.91 million for the quarter, compared to analyst estimates of $37.48 million. Quanterix had a negative net margin of 80.25% and a negative return on equity of 24.77%.

Here are the key takeaways from Quanterix’s conference call:

• 2026 revenue guidance was cut substantially to $142 million–$148 million from $169 million–$174 million, reflecting a broad-based Q2 shortfall, weak academic/government spending, market softness, and commercial execution issues.
• Q3 revenue is expected to be flat to slightly above Q2, while cash-flow breakeven has been delayed to 2027; the company expects double-digit cash usage in Q3 and approximately $80 million of cash at year-end, versus roughly $100 million previously.
• Quanterix is reorganizing its commercial operation around solution-based selling and adding experienced leaders, including Jim Gute as chief commercial officer, to improve sales productivity across Simoa, Spatial, and Accelerator.
• The company reported encouraging indicators, including sequentially higher bookings and a 1.0 book-to-bill ratio, sequential growth in pharma revenue, increased LucentAD Complete test volume, and new spatial and neurology assay launches.
• Quanterix highlighted growing support for its Alzheimer’s diagnostics strategy: LucentAD Complete has CMS pricing of $897, gained Anthem coverage effective July 1 when medical-necessity criteria are met, and remains in productive FDA discussions with potential clearance expected toward year-end.

Quanterix Trading Up 8.7%

NASDAQ:QTRX opened at $2.63 on Wednesday. The firm has a market cap of $123.90 million, a price-to-earnings ratio of -1.00 and a beta of 1.07. The company’s 50-day moving average is $3.67 and its two-hundred day moving average is $4.14. Quanterix has a 12-month low of $2.15 and a 12-month high of $8.77.

Wall Street Analysts Forecast Growth

QTRX has been the topic of a number of research reports. Wall Street Zen upgraded Quanterix from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Quanterix in a report on Friday. TD Cowen dropped their price target on Quanterix from $4.00 to $3.00 and set a “hold” rating for the company in a research report on Tuesday. Finally, Canaccord Genuity Group cut their price target on Quanterix from $8.00 to $4.00 and set a “hold” rating for the company in a research note on Monday, April 20th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Quanterix currently has a consensus rating of “Reduce” and an average target price of $3.50.

Institutional Trading of Quanterix

Hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Quanterix during the 4th quarter valued at about $27,000. Quarry LP grew its stake in shares of Quanterix by 277,300.0% during the 3rd quarter. Quarry LP now owns 5,548 shares of the company’s stock valued at $30,000 after buying an additional 5,546 shares during the period. Renaissance Technologies LLC purchased a new stake in Quanterix during the fourth quarter valued at about $75,000. HUB Investment Partners LLC acquired a new stake in Quanterix during the 2nd quarter worth approximately $81,000. Finally, HRT Financial LP acquired a new stake in shares of Quanterix in the fourth quarter worth $82,000. 86.48% of the stock is owned by hedge funds and other institutional investors.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.